Author pages are created from data sourced from our academic publisher partnerships and public sources.
Share This Author
Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures
Among women with low bone mass and existing vertebral fractures, alendronate is well tolerated and substantially reduces the frequency of morphometric and clinical vertebra fractures, as well as other clinical fractures. Expand
Risk factors for hip fracture in white women. Study of Osteoporotic Fractures Research Group.
Women with multiple risk factors and low bone density have an especially high risk of hip fracture and maintaining body weight, walking for exercise, avoiding long-acting benzodiazepines, minimizing caffeine intake, and treating impaired visual function are among the steps that may decrease the risk. Expand
Gait speed and survival in older adults.
In this pooled analysis of individual data from 9 selected cohorts, gait speed was associated with survival in older adults and predicted survival was as accurate as predicted based on age, sex, use of mobility aids, and self-reported function. Expand
Bisphosphonate‐Associated Osteonecrosis of the Jaw: Report of a Task Force of the American Society for Bone and Mineral Research
- S. Khosla, D. Burr, +21 authors E. Shane
- Journal of bone and mineral research : the…
- 1 October 2007
This report summarizes the findings and recommendations of the task force to address key questions related to case definition, epidemiology, risk factors, diagnostic imaging, clinical management, and future areas for research related to the disorder. Expand
Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis.
- D. Black, P. Delmas, +18 authors S. Cummings
- The New England journal of medicine
- 1 August 2007
A once-yearly infusion of zoledronic acid during a 3-year period significantly reduced the risk of vertebral, hip, and other fractures and was associated with a significant improvement in bone mineral density and bone metabolism markers. Expand
Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial.
The results suggest that for many women, discontinuation of alendronate for up to 5 years does not appear to significantly increase fracture risk, however, women at very high risk of clinical vertebral fractures may benefit by continuing beyond 5 years. Expand
Genome-wide meta-analysis identifies 56 bone mineral density loci and reveals 14 loci associated with risk of fracture
- K. Estrada, U. Styrkarsdottir, +178 authors F. Rivadeneira
- Medicine, Biology
- Nature Genetics
- 9 April 2012
Light is shed on the genetic architecture and pathophysiological mechanisms underlying BMD variation and fracture susceptibility and within the RANK-RANKL-OPG, mesenchymal stem cell differentiation, endochondral ossification and Wnt signaling pathways. Expand
Calcium plus vitamin D supplementation and the risk of fractures.
- R. Jackson, A. LaCroix, +44 authors D. Barad
- The New England journal of medicine
- 16 February 2006
Among healthy postmenopausal women, calcium with vitamin D supplementation resulted in a small but significant improvement in hip bone density, did not significantly reduce hip fracture, and increased the risk of kidney stones. Expand
Common genetic determinants of vitamin D insufficiency: a genome-wide association study
Variants near genes involved in cholesterol synthesis, hydroxylation, and vitamin D transport affect vitamin D status, and genetic variation at these loci identifies individuals who have substantially raised risk of vitamin D insufficiency. Expand
Comparison of 2 frailty indexes for prediction of falls, disability, fractures, and death in older women.
The simple SOF index predicts risk of falls, disability, fracture, and death as well as the more complex CHS index and may provide a useful definition of frailty to identify older women at risk of adverse health outcomes in clinical practice. Expand